Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
The analyst sees zele with a potential high-opportunity Nectin-4 conjugate for solid tumors, with an estimated ~$2 billion at peak global sales in 2033.RBC Capital initiated coverage on Bicycle Therapeutics PLC (NASDAQ:BCYC), noting an advantage in oncology and beyond.
RBC Capital開始對Bicycle Therapeutics PLC（納斯達克: BCYC）進行覆蓋，指出其在腫瘤學和其他領域具有優勢。
The analyst writes the company's lead program, Zelenectide pevedotin (zele, formerly BT8009), shows potential to compete in metastatic urothelial cancer (mUC) due to similar objective response rates and fewer adverse events compared to Pfizer Inc's (NYSE:PFE) Seagen Inc. drug, Padcev.
分析師指出，該公司的主導項目Zelenectide pevedotin（zele，以前稱爲BT8009）在轉移性膀胱癌（mUC）中顯示出與輝瑞公司（紐交所:PFE）的Seagen Inc.藥物Padcev相似的客觀反應率和更少的不良事件競爭潛力。
The improved safety profile of Zelenectide could result in greater antitumor durability, a key differentiator from Padcev.
Zelenectide更好的安全性能可能會導致更長的抗腫瘤耐藥性，與Padcev不同的一個關鍵點。
The analyst sees zele with a potential high-opportunity Nectin-4 conjugate for solid tumors, with an estimated ~$2 billion at peak global sales in 2033.
分析師認爲，對於實體腫瘤，zele具有潛在的高機會Nectin-4結合物，預計2033年全球銷售額將達到約20億美元。
RBC writes, "Commercialization opportunities in non-mUC indications are likely less competitive and offer additional upside to zele."
RBC表示:"非轉移性膀胱癌的商業機會可能競爭較小，併爲zele提供額外的增長空間。"
The analyst initiates with an Outperform rating and a price target of $35.
分析師給予Outperform評級和35美元的目標股價。
The RBC Capital analyst views the regulatory path for Zele as de-risked following FDA alignment on the Duravelo-2 trial. RBC's proprietary oncologist survey highlights strong demand for a safer Nectin-4 drug conjugate.
RBC Capital分析師認爲，在FDA的Duravelo-2試驗上達成一致後，Zele的監管路徑已減少風險。RBC的專有腫瘤學家調查強調，對於更安全的Nectin-4結合物存在強烈的需求。
The analyst also notes Zele's potential therapeutic value in additional solid tumor indications, such as triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC), which Padcev has yet to address.
分析師還指出，Zele在其他實體腫瘤指標中具有潛在的治療價值，例如三陰性乳腺癌（TNBC）和非小細胞肺癌(NSCLC)，這些指標是Padcev尚未解決的。
The analyst highlights the strong potential of Bicycle Therapeutics' pipeline, which includes two additional clinical-stage candidates. Early signs of activity and safety indicate promise for both candidates in treating solid tumors.
分析師強調了Bicycle Therapeutics的產品線的巨大潛力，其中包括兩個其他臨床階段候選藥物。早期的活動和安全性跡象表明這兩個候選藥物在治療實體瘤方面具有潛力。
The Bicycle platform has been proven through clinical data from its internal pipeline and various external partnerships, generating over $200 million in non-dilutive capital. Future value creation is anticipated from next-generation Bicycle Toxin Conjugates (BTCs), radiopharmaceutical applications, and expansion into areas beyond oncology.
通過其內部產品線和各種外部合作伙伴關係的臨床數據，Bicycle平台已經得到驗證，產生了超過2,000萬美元的非稀釋性資本。未來的價值創造預計將來自下一代Bicycle毒素偶聯物（BTCs），放射藥物應用以及擴展到腫瘤以外的領域。
As of June 30, 2024, cash and cash equivalents were $961.4 million, which is expected to provide a cash runway into the second half of 2027.
截至2024年6月30日，現金及現金等價物爲96140萬美元，預計足夠支持至2027年下半年。
Price Action: BCYC stock is up 1.27% at $20.69 at the last check on Friday.
價格走勢：BCYC股票在上週五最後一次查詢時上漲1.27%，報20.69美元。
- FDA Battles Backlog of Drug Factory Inspections Since COVID-19.
- 美國食品藥品監督管理局在COVID-19疫情以來一直與待審的藥品工廠巡查堆積進行鬥爭。
